{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:17:39Z","timestamp":1790227059413,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T00:00:00Z","timestamp":1182902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T00:00:00Z","timestamp":1182902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00280-007-0530-8","type":"journal-article","created":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T07:50:36Z","timestamp":1182844236000},"page":"751-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Phase\u00a0I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone\u00a0B analog, in Japanese patients with refractory solid tumors"],"prefix":"10.1007","volume":"61","author":[{"given":"Toshio","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Fujisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Tokudome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Klimovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,27]]},"reference":[{"key":"530_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1200\/JCO.2003.03.063","volume":"21","author":"J Abraham","year":"2003","unstructured":"Abraham J, Agrawal M, Bakke S et al (2003) Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21:1866\u20131873","journal-title":"J Clin Oncol"},{"issue":"9","key":"530_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1200\/JCO.2006.08.7304","volume":"25","author":"C Aghajanian","year":"2007","unstructured":"Aghajanian C, Burris HA 3rd, Jones S et al (2007) Phase I study of the novel epothilone analog Ixabepilone (BMS-247550) in patient with advanced solid tumors and lymphomas. J Clin Oncol 25(9):1082\u20131088","journal-title":"J Clin Oncol"},{"key":"530_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10637-006-7304-8","volume":"24","author":"JA Ajani","year":"2006","unstructured":"Ajani JA, Safran H, Bokemeyer C et al (2006) A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 24:441\u2013446","journal-title":"Invest New Drugs"},{"key":"530_CR4","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.2174\/1381612023394043","volume":"8","author":"R Altaha","year":"2002","unstructured":"Altaha R, Fojo T, Reed E et al (2002) Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr Pharm Des 8:1707\u20131712","journal-title":"Curr Pharm Des"},{"key":"530_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/1389557033405269","volume":"3","author":"KH Altmann","year":"2003","unstructured":"Altmann KH (2003) Epothilone B and its analogs\u2014a new family of anticancer agents. Mini Rev Med Chem 3:149\u2013158","journal-title":"Mini Rev Med Chem"},{"key":"530_CR6","first-page":"M79","volume":"1470","author":"KH Altmann","year":"2000","unstructured":"Altmann KH, Wartmann M, O\u2019Reilly T (2000) Epothilones and related structures\u2014a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470:M79\u2013M91","journal-title":"Biochim Biophys Acta"},{"key":"530_CR7","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1021\/bi0121611","volume":"41","author":"CJ Bode","year":"2002","unstructured":"Bode CJ, Gupta ML Jr, Reiff EA et al (2002) Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 41:3870\u20133874","journal-title":"Biochemistry"},{"key":"530_CR8","first-page":"1195","volume":"2","author":"TA Brooks","year":"2003","unstructured":"Brooks TA, Minderman H, O\u2019Loughlin KL et al (2003) Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195\u20131205","journal-title":"Mol Cancer Ther"},{"key":"530_CR9","doi-asserted-by":"crossref","first-page":"568s","DOI":"10.1200\/jco.2006.24.18_suppl.568","volume":"24","author":"CA Bunnell","year":"2006","unstructured":"Bunnell CA, Klimovsky J, Thomas E (2006) Final efficacy results of a phase I\/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. Proc Am Soc Clin Oncol 24:568s","journal-title":"Proc Am Soc Clin Oncol"},{"key":"530_CR10","first-page":"429","volume":"20","author":"P Calvert","year":"2001","unstructured":"Calvert P, O\u2019Neill V, Twelves C (2001) A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:abstract 429","journal-title":"Proc Am Soc Clin Oncol"},{"key":"530_CR11","doi-asserted-by":"crossref","unstructured":"Dickson N, Peck R, Wu C et al (2006) Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a Phase I trial. J Clin Oncol 24:abstract 2040","DOI":"10.1200\/jco.2006.24.18_suppl.2040"},{"key":"530_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdh236","volume":"15","author":"C Eng","year":"2004","unstructured":"Eng C, Kindler HL, Nattam S et al (2004) A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15:928\u2013932","journal-title":"Ann Oncol"},{"key":"530_CR13","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1158\/1078-0432.CCR-05-0127","volume":"11","author":"SM Gadgeel","year":"2005","unstructured":"Gadgeel SM, Wozniak A, Boinpally RR et al (2005) Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 11:6233\u20136239","journal-title":"Clin Cancer Res"},{"key":"530_CR14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.2005.09.042","volume":"23","author":"MD Galsky","year":"2005","unstructured":"Galsky MD, Small EJ, Oh WK et al (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439\u20131446","journal-title":"J Clin Oncol"},{"key":"530_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1200\/JCO.20.2.574","volume":"20","author":"H Gelderblom","year":"2002","unstructured":"Gelderblom H, Mross K, ten Tije AJ et al (2002) Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20:574\u2013581","journal-title":"J Clin Oncol"},{"key":"530_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-8258(03)00006-4","volume":"89","author":"D Griffin","year":"2003","unstructured":"Griffin D, Wittmann S, Guo F et al (2003) Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L\/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol Oncol 89:37\u201347","journal-title":"Gynecol Oncol"},{"key":"530_CR17","unstructured":"Jordan MA, Miller H, Ni L et al (2006) The Pat-21 breast cancer model derived from a patient with primary Taxol\u00ae resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res 47:abstract LB-280"},{"key":"530_CR18","unstructured":"Lee F, Castenada S, Hawkin D et al (2005) Bevacizumab\/ixabepilone (BMS-247550) combination produces synergistic antitumor efficacy in multiple tumor models in vivo and is superior to bevacizumab\/paclitaxel combination. In: AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics: discovery, biology, and clinical applications. Abstract 3243"},{"key":"530_CR19","first-page":"1429","volume":"7","author":"FY Lee","year":"2001","unstructured":"Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429\u20131437","journal-title":"Clin Cancer Res"},{"key":"530_CR20","first-page":"263","volume":"9","author":"FY Lee","year":"2003","unstructured":"Lee FY, Camuso A, Castaneda S et al (2003) Combinations of the novelepothilone BMS-247550 with selected chemotherapeutic agents produce synergistic anti-neoplastic efficacy in preclinical in vitro and in vivo human cancer models. Clin Cancer Res 9:abstract 263","journal-title":"Clin Cancer Res"},{"key":"530_CR21","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","volume":"24","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633\u20131642","journal-title":"J Clin Oncol"},{"key":"530_CR22","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","volume":"23","author":"JA Low","year":"2005","unstructured":"Low JA, Wedam SB, Lee JJ et al (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726\u20132734","journal-title":"J Clin Oncol"},{"key":"530_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-0919-03","volume":"10","author":"S Mani","year":"2004","unstructured":"Mani S, McDaid H, Hamilton A et al (2004a) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289\u20131298","journal-title":"Clin Cancer Res"},{"issue":"6","key":"530_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/01.cad.0000131681.21637.b2","volume":"15","author":"S Mani","year":"2004","unstructured":"Mani S, Macapinlac M Jr, Colevas D et al (2004b) The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 15(6):553\u2013558","journal-title":"Anticancer Drugs"},{"issue":"1","key":"530_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/annonc\/mdl315","volume":"18","author":"S Mani","year":"2007","unstructured":"Mani S, McDaid HM, Egorin MJ et al (2007) Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol 18(1):190\u2013195","journal-title":"Ann Oncol"},{"key":"530_CR26","first-page":"2035","volume":"8","author":"HM McDaid","year":"2002","unstructured":"McDaid HM, Mani S, Shen HJ et al (2002) Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8:2035\u20132043","journal-title":"Clin Cancer Res"},{"key":"530_CR27","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","volume":"11","author":"S Mielke","year":"2005","unstructured":"Mielke S, Sparreboom A, Steinberg SM et al (2005) Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843\u20134850","journal-title":"Clin Cancer Res"},{"key":"530_CR28","first-page":"599","volume":"1","author":"T Ohtsu","year":"1995","unstructured":"Ohtsu T, Sasaki Y, Tamura T et al (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599\u2013606","journal-title":"Clin Cancer Res"},{"key":"530_CR29","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1200\/jco.2004.22.90140.7542","volume":"22","author":"AC Pavlick","year":"2004","unstructured":"Pavlick AC, Millward M, Farrell K et al (2004) A phase II study of the epothilone B analog (epoB)- BMS-247550 (NSC#710428) in stage IV malignant melanoma (MM). J Clin Oncol 22:abstract 7542","journal-title":"J Clin Oncol"},{"key":"530_CR30","first-page":"135","volume":"22","author":"L Piro","year":"2003","unstructured":"Piro L, Rosen L, Parson M (2003) KOS-862 (epothiolone D): a comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:135","journal-title":"Proc Am Soc Clin Oncol"},{"key":"530_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0093-7754(03)00125-8","volume":"30","author":"J Rothermel","year":"2003","unstructured":"Rothermel J, Wartmann M, Chen T et al (2003) EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol 30:51\u201355","journal-title":"Semin Oncol"},{"key":"530_CR32","first-page":"2301","volume":"22","author":"SS Shord","year":"2002","unstructured":"Shord SS, Bernard SA, Lindley C et al (2002) Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anticancer Res 22:2301\u20132309","journal-title":"Anticancer Res"},{"key":"530_CR33","first-page":"2519","volume":"22","author":"JF Vansteenkiste","year":"2003","unstructured":"Vansteenkiste JF, Breton JL, Sandler A et al (2003) A randomised phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 22:abstract 2519","journal-title":"Proc Am Soc Clin Oncol"},{"key":"530_CR34","doi-asserted-by":"crossref","unstructured":"Whitehead RP, McCoy S, Rivkin SE et al (2006) A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a southwest oncology group study. Invest New Drugs [Epub ahead of print]","DOI":"10.1007\/s10637-006-8440-x"},{"key":"530_CR35","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/cncr.20977","volume":"103","author":"SH Zhuang","year":"2005","unstructured":"Zhuang SH, Agrawal M, Edgerly M (2005) A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3\u00a0days. Cancer 103:1932\u20131938","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-007-0530-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0530-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:37:33Z","timestamp":1659058653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-007-0530-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,27]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0530-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,27]]},"assertion":[{"value":"3 January 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}